Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Two-Cohort Study of Eliglustat in Pediatric Gaucher Disease Types 1 and 3
2016-000301-37Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of eliglustat in Gaucher disease type 1 (GD1) and Gaucher disease type 3 (2 arms), sponsored by Sanofi. Primary endpoint: Maximum plasma concentration (Cmax) of eliglustat. Started Jun 2018; status: completed.
02
Drugs
eliglustat
03
Conditions
Gaucher disease type 1 (GD1)Gaucher disease type 3
Beyond the preview
Go deeper on 2016-000301-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000301-37.